Allergan

NEWARK, N.J. – Allergan shareholders say in a federal class action that drugmaker’s stock dropped 41 percent, from $319.47 in 2015 to $188.82 last month, upon news that it could face criminal charges for colluding to fix the prices of generic pharmaceuticals.